Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

STATUS

Recruiting
End date

Aug 9, 2026
participants needed

62
sponsor

St. Jude Children's Research Hospital

Updated on 9 June 2022

See if I qualify

Summary

This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH.

Primary Objective

To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newly diagnosed HLH.

Secondary Objectives

To describe the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with relapsed/refractory HLH.
To describe the overall response and outcome for patients with newly diagnosed or relapsed/refractory HLH who are treated with this response-adapted ruxolitinib-containing regimen.

Exploratory Objectives

To estimate the pharmacokinetic (PK) parameters of ruxolitinib, assess covariates of ruxolitinib pharmacokinetics, and test whether the drug's effectiveness is correlated with systemic drug exposure.
To query specific immunologic biomarkers and determine whether the levels of these biomarkers correlate with disease response and outcome.

Description

Frontline Arm: Safety Phase and Expansion Phase

Safety Phase: The Frontline Arm will begin with a Safety Phase to identify a feasible and safe dose of ruxolitinib to be given in combination with the "gold standard" HLH-directed agents dexamethasone and etoposide. For this part of the trial, a minimum of 6 newly diagnosed HLH patients will be included. These patients will first receive ruxolitinib 25 mg/m^2/dose by mouth BID (twice a day), dexamethasone 5 mg/m^2/dose PO or IV BID, and etoposide 150 mg/m^2/dose IV weekly. Etoposide dosing is to be initiated within the first 24-48 hours. The first dose of dexamethasone and etoposide will be at least 8 hours after the first dose of ruxolitinib for PK testing purposes, but patients will not be excluded if dexamethasone has already been started before initiating ruxolitinib. The dose of ruxolitinib may be escalated or de-escalated as needed, based on observed toxicities and surrogates of disease response. Dexamethasone will be weaned every 2 weeks. In case of disease reactivation, patients will receive individualized re-intensification.

Expansion Phase: When a dose of ruxolitinib deemed feasible and safe is identified, the Expansion Phase of the Frontline Arm will begin. Patients with newly diagnosed HLH in the Expansion Phase will receive ruxolitinib (at the maximally tolerated dose [MTD] established in the Safety Phase) and dexamethasone 5 mg/m^2/dose by mouth or IV BID. The first dose of dexamethasone will be given at least 8 hours after the first dose of ruxolitinib for PK testing purposes, but patients will not be excluded if dexamethasone has already been started before initiating of ruxolitinib. Disease response evaluations will be completed at 1, 2, 4, 6, and 8 weeks. Treatment will be individualized based on response.

Patients whose HLH responds favorably after 1 week (SD 8) of therapy (e.g., favorable response (FR), Week 1) will remain on ruxolitinib and dexamethasone. As long as patients show a CR or partial response (PR) at Week 2 (SD15), ruxolitinib and dexamethasone are tolerated, and patients are clinically stable, they will remain on both agents for the remainder of the 8-week study period. Dexamethasone will be weaned every 2 weeks as tolerated. In case of disease reactivation, therapy will be re-intensified.

Patients whose HLH responds unfavorably after 1 week (SD8) of therapy (e.g., unfavorable response, Week 1) will have etoposide added (150 mg/m^2/dose, IV weekly). As long as patients show CR or PR at Week 2 (SD15), combination treatment with ruxolitinib, dexamethasone, and etoposide is tolerated, and patients are clinically stable, they will remain on these 3 agents for the remainder of the 8-week study period. Dexamethasone will not be weaned until patients have shown at least a PR, with the weaning schedule determined by the treating physician. Dexamethasone weaning may continue beyond the 8-week study period. Patients whose HLH does not respond favorably (e.g., exhibit non-response (NR), progressive disease (PD)) despite treatment with ruxolitinib, dexamethasone, and etoposide will be taken off treatment and salvage therapy will be considered and decided by the treating physician.

Salvage Arm: Patients with relapsed/refractory HLH will be treated on the Salvage Arm. They will not be included in the Safety Phase; instead, they will be treated using the response-adapted approach. Patients may be enrolled on the Salvage Arm as the Safety Phase is ongoing. Patients will receive ruxolitinib 25 mg/m^2/dose by mouth BID and dexamethasone 5 mg/m^2/dose by mouth or IV BID. The first dose of dexamethasone will be given at least 8 hours after the first dose of ruxolitinib for PK testing purposes, but patients will not be excluded if dexamethasone has already been started before starting ruxolitinib. Disease response evaluations will be completed at 1, 2, 4, 6, and 8 weeks. Treatment will be individualized based on response as described for the Expansion Phase of the Frontline Arm. When the MTD of ruxolitinib has been determined on the Safety Phase of the Frontline Arm, it will be the dose used for any additional patients enrolled on the Salvage Arm. Any patients already on the Salvage Arm who show no adverse effects or toxicity at an assigned dose of 25 mg/m^2 BID will be continued on this dose for the 8 week study period.

HLH Reactivation: For patients who initially respond favorably but then worsen (e.g., "reactivate") during the later phases of induction when dexamethasone is weaned, dexamethasone will be increased back to 5 mg/m^2/dose PO/IV BID (10 mg/m^2/day). If the patient is on a reduced dose of ruxolitinib due to prior toxicity(ies), the ruxolitinib dose may be increased to patient's starting dose, provided the prior toxicity(ies) has resolved for at least 1 week. Patients whose HLH responds favorably will continue to receive ruxolitinib and dexamethasone or ruxolitinib, dexamethasone and etoposide. Patients receiving ruxolitinib, dexamethasone and etoposide whose HLH responds unfavorably will be taken off treatment and be considered for an alternative salvage therapy. For patients receiving ruxolitinib and dexamethasone whose HLH responds unfavorably, etoposide may be added. If the response is favorable, the patient will continue on all 3 medications. If the response is unfavorable after adding etoposide, the patient will be taken off treatment and will be considered for an alternative salvage therapy.

All patients with CNS disease will receive intrathecal (IT) MTX and hydrocortisone (HC), per age-based dosing, once per week for up to 4 weeks.

Patients will be followed for one year after starting protocol therapy or 1 year after HSCT (for those undergoing HSCT).

Details

Condition	Hemophagocytic Lymphohistiocytosis
Treatment	etoposide, Ruxolitinib, Dexamethasone
Clinical Study Identifier	NCT04551131
Sponsor	St. Jude Children's Research Hospital
Last Modified on	9 June 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Frontline Arm
	Patient is ≥6 weeks and ≤22 years of age
	Patient weighs ≥3 kg
	Patient is able to take medication PO and/or patient or parent is willing to have NG tube placed if patient is unable to take medications PO
	Patient has active HLH if ≥5 of 8 HLH-2004 diagnostic criteria listed below OR patient has known fHLH (e.g., patient has pathogenic/likely pathogenic germline variant(s) in genes such as PRF1, UNC13D, STX11, STXBP2, LYST, RAB27A, XIAP, SH2D1A, NLCR4) and meets ≥4 of the HLH-2004 diagnostic criteria listed below
	Fever
	Splenomegaly
	Cytopenias affecting ≥2 of 3 cell lineages in the peripheral blood (hemoglobin <9 g/dL, platelets <100 × 10^9/L, neutrophils <1000 × 10^6/L)
	Hypertriglyceridemia (fasting triglycerides ≥265 mg/dL) or hypofibrinogenemia (fibrinogen ≤150 g/dL)
	Presence of hemophagocytosis in BM or other tissues
	Low or absent NK-cell activity OR decreased CD107a mobilization
	Ferritin ≥500 ng/mL
	Soluble IL-2 receptor (CD25) ≥2400 U/mL
	Patient has not received prior HLH therapy, except steroids (any dose is allowed, but
	Patient, parent, or legal authorized representative (LAR) must provide informed consent
	patient must not have been treated for more than 2 consecutive weeks) OR
	anakinra (any dose or length of therapy is allowed)
	Inclusion Criteria: Salvage Arm
	Patient or parent is willing to have the NG tube placed if patient is unable to take medications PO
	Patient is ≥6 weeks and ≤22 years of age
	Patient weighs ≥3 kg
	Patient must have active HLH at the time of eligibility assessment, defined as 3 or more of the following Relapsed/Refractory HLH Criteria
	Fever
	Patient has past history of HLH, defined as meeting ≥5 of 8 HLH- 2004 diagnostic criteria for those with no known HLH-associated mutations, OR ≥4 of 8 HLH-2004 diagnostic criteria for those with known familial disease
	Splenomegaly (recurrent or worsening)
	Hypofibrinogenemia (fibrinogen <150 g/dL)
	Neutrophils <1000 × 10^6/L × 2 assessments over at least 3 days OR platelets <100 × 10^9/L × 2 assessments over at least 3 days, OR need for platelet transfusions
	Worsening CNS symptoms OR new abnormal brain magnetic resonance imaging (MRI) findings deemed consistent with CNS HLH by the primary treating physician OR CSF cell count >5 (with or without hemophagocytosis) OR CSF protein higher than the institutional upper limit of normal OR CSF neopterin higher than the institutional upper limit of normal
	Soluble IL-2 receptor level ≥ 2400 U/L
	Presence of hemophagocytosis in the BM or other tissues
	Increasing ferritin × 2 assessments over at least 3 days (both levels must be >2000 ng/dL)
	Patient must have received prior HLH-directed therapy
	Patient must be deemed by the primary treating physician to have not responded to
	At least 2 weeks of steroids (equivalent to at least 5 mg/m^2/day dexamethasone or 1 mg/kg/day methylprednisolone) AND at least 2 doses of etoposide (with at least 7 days between the last etoposide dose and starting ruxolitinib); OR
	prior therapy by either not having or maintaining a response
	At least 1 dose of ATG (with at least 7 days between the last ATG dose and starting ruxolitinib)
	Patient or parent/LAR must provide informed consent
Exclusion Criteria
	Frontline and Salvage Arms
	Patient is <6 weeks or >22 years of age
	Patient weighs <3 kg
	Patient has isolated CNS disease
	Life expectancy is <2 weeks
	Patient is likely to require <4 weeks of therapy (i.e., HSCT is imminent)
	Patients with creatinine clearance (CrCl) <15 mL/min who are NOT receiving dialysis
	Patient has evidence of severe organ dysfunction, defined as: Severe liver dysfunction (ALT >1000 U/L), OR Cardiorespiratory failure requiring any ionotropic support OR extracorporeal life support, OR high frequency oscillatory ventilation, other forms of respiratory support or ventilation are allowed if the patient is not on vasopressors)
	Patient with pre-existing rheumatologic disorder
	Patient with known active malignancy
	Patient with previous HSCT, except when HSCT was for treatment of HLH
	Patient is pregnant or lactating
	Patients who expect to conceive or father children within the projected duration of the study and/or who are unwilling to use highly effective methods of contraception throughout the duration of the study, starting with the screening visit through the end of the treatment visit
	Patient has suspected or known fungal disease
	Patient is unable to tolerate administration of drugs PO or NG
	Patient is taking rifampin or St. John's Wort
	Patient is taking another investigational agent or is enrolled on another treatment protocol
	Patient, parent, or LAR are unable or unwilling to provide informed consent
	Additional Exclusion Criteria for the Frontline Arm
	Patient has or is receiving treatment with a JAK inhibitor (including ruxolitinib), ATG, alemtuzumab, etoposide, tocilizumab, emapalumab or any other HLH-directed therapy other than steroids or anakinra (as defined in the Frontline Arm Inclusion Criteria, #5)
	Additional Exclusion Criteria for the Salvage Arm
	Patient has or is receiving treatment with a JAK inhibitor (including ruxolitinib), tocilizumab, alemtuzumab, OR emapalumab within the last 3 months
	Patient has received therapy on the Frontline Arm of this trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis